Drug Database
Back to search

Netherlands· NL-15266bee8f2a

Orgovyx 120 mg, filmomhulde tabletten

A relugolix product containing relugolix, registered in Netherlands by Accord Healthcare S.L.U.. The same ATC class is registered in 15 of our 19 countries.

ATC L02BX04

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedOrgovyx 120 mg, filmomhulde tablettenATCL02BX04REGISTER NO.NL-15266bee8f2aPACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about relugolixAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Relugolix is registered in 15 of 19 countries.

Countries holding a registration under ATC L02BX04 (relugolix), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 10 of them publish a price we can compare per daily dose
Search relugolix products by name

Relugolix · ATC L02BX04

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of relugolix costs, country by country.

Normalised to the WHO defined daily dose (0.12 g), the median price runs from $3.40 in France to $9.83 in Italy — a ×2.9 gap.

  • 4 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Relugolix · price per daily dose (0.12 g)

USD · FX 28 Sept 2026

  • IT Italy$9.83
  • ES Spain$7.69
  • CH Switzerland$6.03
  • FR France$3.40
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
RELUGOLIX
Manufacturer
Accord Healthcare S.L.U.
Country
Netherlands (NL)
ATC code
L02BX04
ATC class
Relugolix
Defined daily dose
0.12 g, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/22/1642

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

168 interactions on record for relugolix.

Graded by severity as the source publishes them — 52 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check relugolix against other medicinesHow interaction checks work

Relugolix · interactions on record

168 records

  • 52 severe
  • 101 moderate
  • 15 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • DolasetronA04AA04severe
  • RolapitantA04AD14severe
  • FidaxomicinA07AA12severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Relugolix in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All relugolix products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Orgovyx
  • Liechtenstein · Orgovyx
  • Norway · Orgovyx

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f0473fd8-7770-4e73-b8a5-d8d69b6dc901
GET /v1/drugs/f0473fd8-7770-4e73-b8a5-d8d69b6dc901?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/orgovyx-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Relugolix",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp128096",
  "excipients": [
    "CARNAUBAWAS (E 903)",
    "HYPROLOSE (E 463)",
    "HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
    "IJZEROXIDE ROOD  (E 172)",
    "MAGNESIUMSTEARAAT (E 470b)",
    "MANNITOL (D-) (E 421)",
    "NATRIUMZETMEELGLYCOLAAT",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "RELUGOLIX"
  ],
  "leaflet_url": null,
  "authorised_at": "2022/07/08",
  "procedure_number": "EMEA/H/C/005353",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/22/1642",
  "additional_monitoring": "Y"
}
API referenceMCP serverPlans

See everything about relugolix.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console